Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Bristol-Myers Squibb and Merck & Co, Inc.
Management of Patients with Skin Cancers: Basal Cell Carcinoma and Melanoma
Daniel M. Siegel, MD, MS, FAAD, FACMS
SUNY Downstate Medical Center, Department of Dermatology
Brianna Hoffner, MS, ANP-BC,AOCNP®
Univ of Colorado Cancer Center
Novel, cutting-edge therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique, potentially severe or even lethal immune-related adverse events (irAEs). Many advanced practitioners lack familiarity with newer immunotherapies and hedgehog inhibitors. This learning activity will equip APs with the knowledge needed to provide safe, state-of-the-art care for their patients with melanoma or basal cell skin cancer.
These CME/CE/CPE accredited activities are jointly provided by
